Clinical trial NCT00612989: Ph I 5-day Temozolomide + O6-BG in Treatment of Pts w Recurrent / Progressive GBM
Official title: Phase I Trial of a 5-day Regimen of Temodar Plus O6-Benzylguanine (O6-BG) in the Treatment of Patients With Recurrent / Progressive Glioblastoma Multiforme
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Glioblastoma
Gliosarcoma
Keywords: Glioblastoma
Gliosarcoma
GBM
Temodar
Temozolomide
O6-BG
O6-Benzylguanine
Recurrent GBM
Progressive GBM
Brain tumor
Malignant glioma
Neulasta
Pegfilgrastim
Lead sponsor: Duke University
Sponsor class: OTHER
Collaborators: name: Schering-Plough
name: Keryx / AOI Pharmaceuticals, Inc.
First posted: 2008-02-12
Enrollment: 42
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Primary objectives To determine maxi tolerated dose of Temodar® in combo w O6-benzylguanine administered for 5 consecutive days in pts w progressive/recurrent GBM To characterize toxicity associated w Temodar® in combo w O6-BG administered for 5 consecutive days in pts w progressive/recurrent GBM To determine Neulasta®-supported MTD defined as the MTD of Temodar® in combo with O6-BG administered for 5 days while receiving Neulasta® once per treatment cycle between days 7 \& 14 in pts w progressive/recurrent GBM To obtain preliminary response rates of Temodar® in combo w O6-BG administered for 5 consecutive days in pts w progressive/recurrent GBM

Detailed description: 1 primary objective is to determine maximum tolerated dose of Temodar in combo w O6-benzylguanine administered for 5 consecutive days in pts w progressive/recurrent GBM. Another primary objective is to characterize toxicity associated w Temozolomide in combo w O6-BG administered for 5 consecutive days in pts w progressive/recurrent GBM. 3rd primary objective is to determine Neulasta-supported MTD defined as MTD of Temozolomide in combo w O6-BG administered for 5 days while receiving Neulasta once per treatment cycle between days 7 \& 14 in pts w progressive/recurrent GBM. Secondary objective is to obtain preliminary response rates of Temodar in combo w O6-BG administered for 5 consecutive days in pts w progressive/recurrent GBM. Population is Glioblastoma. O6-BG Administration: O6-BG 120mg/m2 administered intravenously over 1 hr followed by continuous infusion of O6-BG at 30mg/m2/day for 5 consecutive days. Every 48hrs repeat dose of 120mg/m2 over 1hr administered for total of 3 doses.

Temodar Administration: Temodar administered orally, in fasting state within 60 mins of end of 1st 1-hr infusion of O6-BG \& then every 24 hrs during continuous infusion of O6-BG. Temozolomide administered on day 1 of treatment cycle and every 24 hrs thereafter for 5 days w treatment cycles repeated every 28 days. Body surface area calculated at beginning of each cycle will be used to calculate daily dose of Temozolomide administered for that cycle.

Neulasta Administration. Neulasta administered by subcutaneous injection in 0.6mL pre-filled syringe containing 6mg of pegfilgrastim. It will be administered once per chemotherapy cycle between days 7 \& 14. Neulasta should not be administered in period between 14 days before \& 24hrs after administration of cytotoxic chemo including Temozolomide.

Data Analysis will be conducted by Biostatistics department of Duke.

Eligibility criteria: Inclusion Criteria:

* Pts have histologically proven supratentorial GBM
* Pts have recurrent/progressive MG. If pt received stereotactic radiosurgery / brachytherapy as part of their prior therapy, then histologic confirmation of recurrence/metabolic imaging consistent w recurrent tumor is recommended but not mandated
* There must be measurable disease on contrast-enhanced magnetic resonance imaging study / CT scan performed \<2wks of study drug administration
* Interval of \>12 wks between completion of XRT \& enrollment on protocol
* Interval of \>4 wks between prior chemo \& enrollment on protocol unless there is unequivocal evidence of tumor progression
* Interval of \>2 wks between prior surgical resection \& enrollment on protocol unless there is unequivocal evidence of tumor progression
* Age \>18 yrs
* KPS \>70 percent
* Following baseline study will be required \<1wk of study drug administration: serum creatinine \< 1.5 x ULN \& Hematologic Status
* Following baseline studies will be required \<1wk of study drug administration: absolute neutrophil count \>2000 cells/microliter; platelet count \>125,000 cells/microliter
* Following baseline studies will be required \<1 wk of study drug administration: serum SGOT \& total bilirubin \< 2.5 x ULN
* Signed informed consent, approved by IRB, will be obtained prior to initiating treatment
* Pts w Reproductive Potential: Pts must agree to practice effective birth control measures while on study \& for 2 months after completing therapy

Exclusion Criteria:

* Pregnant/breast feeding women/ women/men w reproductive potential not practicing adequate contraception. Therapy may be associated w potential toxicity to fetus/child that exceeds mini risks necessary to meet health needs of mother
* Prior treatment w O6-BG + Temozolomide in combo
* Active infection requiring intravenous antibiotics
* Known diagnosis of HIV infection
* Pts w history of another primary malignancy that is currently clinically significant/currently requires active intervention
* Pts unwilling/unable to comply w protocol due to serious medical/psychiatric condition
* Pts who have received investigational drugs \<2 wks prior to start on study drug/have not recovered from side effects of such therapy.

Primary outcomes:
measure: Dose limiting toxicity
timeFrame: 6 months
Secondary outcomes:
measure: Progression-free survival
timeFrame: 6 months
Other outcomes:
Locations:
city: Durham
country: United States
facility: Duke University Health System
state: North Carolina
Study officials:
affiliation: Duke Health
name: David A. Reardon, MD
role: PRINCIPAL_INVESTIGATOR
References: